SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Oravetz who wrote (263)12/12/2001 3:53:42 PM
From: scaram(o)uche   of 370
 
Jim:

I haven't followed TAPET, but even with the VION bacteria that are LPS disabled, I would imagine that most express concern about systemic toxicity.

When I say "concern", I'm again speaking from the context of "two years of no study" ignorance. I know enough to be careful, and too little to catch any upside given that my concern has no valid foundation. So..... ignore me.

I've worked briefly with Dr. Vogelstein (a SBIR consultant while I was at PharMingen). Yup, he's bright. Not to mention just a tad accomplished.

:-)

Although the JHU stuff doesn't seem to acknowledge VION's work, I'm certain that it's acknowledged in the manuscript (which I should remember to look up when next in the library). Thanks for finding the JHU slant.

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News